BBIO

76.06

3.72% 2.73

Dopo l'orario di chiusura: 76.07 0.010 +0.01%

Bridgebio Pharma Inc (BBIO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BBIO Giù? Forum Previsione

Precedente Chiudi:

$73.33

Aprire:

$84.845

Volume 24 ore:

9.16M

Relative Volume:

3.67

Capitalizzazione di mercato:

$14.58B

Reddito:

$353.78M

Utile/perdita netta:

$-805.69M

Rapporto P/E:

-18.17

EPS:

-4.1869

Flusso di cassa netto:

$-597.61M

1 W Prestazione:

+19.35%

1M Prestazione:

-1.02%

6M Prestazione:

+54.94%

1 anno Prestazione:

+138.06%

Intervallo 1D:

$76.03

$84.94

Intervallo di 1 settimana:

$67.59

$84.94

Portata 52W:

$28.32

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Nome

Bridgebio Pharma Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

(650) 391-9740

Indirizzo

3160 PORTER DR., PALO ALTO, CA

Dipendente

730

Cinguettio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BBIO Bridgebio Pharma Inc	76.06	14.05B	353.78M	-805.69M	-597.61M	-4.1869
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Iniziato	Barclays	Overweight
2026-01-06	Iniziato	Morgan Stanley	Overweight
2025-12-11	Iniziato	Bernstein	Outperform
2025-07-30	Ripresa	Raymond James	Outperform
2025-07-21	Iniziato	Truist	Buy
2025-07-14	Iniziato	Jefferies	Buy
2025-07-09	Aggiornamento	Oppenheimer	Perform → Outperform
2025-06-17	Iniziato	Wolfe Research	Outperform
2025-03-31	Iniziato	Redburn Atlantic	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-10-03	Iniziato	Oppenheimer	Perform
2024-09-04	Iniziato	Piper Sandler	Overweight
2024-03-21	Ripresa	Raymond James	Outperform
2024-01-31	Iniziato	BMO Capital Markets	Market Perform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-11-07	Iniziato	Citigroup	Buy
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-07-18	Downgrade	Jefferies	Buy → Hold
2023-04-19	Iniziato	Evercore ISI	Outperform
2023-02-06	Iniziato	Cowen	Outperform
2021-12-27	Reiterato	Mizuho	Buy
2021-12-27	Reiterato	SVB Leerink	Outperform
2021-09-10	Aggiornamento	BofA Securities	Neutral → Buy
2021-05-21	Iniziato	UBS	Buy
2021-03-22	Reiterato	Goldman	Buy
2021-02-22	Ripresa	JP Morgan	Overweight
2021-02-09	Ripresa	Goldman	Buy
2021-01-11	Reiterato	H.C. Wainwright	Buy
2020-12-10	Reiterato	H.C. Wainwright	Buy
2020-06-25	Iniziato	BofA/Merrill	Neutral
2020-05-19	Iniziato	BTIG Research	Buy
2020-04-13	Iniziato	H.C. Wainwright	Buy
2020-02-19	Iniziato	Mizuho	Buy
2019-07-26	Iniziato	Raymond James	Outperform
2019-07-22	Iniziato	BMO Capital Markets	Outperform
2019-07-22	Iniziato	Goldman	Buy
2019-07-22	Iniziato	JP Morgan	Overweight
2019-07-22	Iniziato	Jefferies	Buy
2019-07-22	Iniziato	Piper Jaffray	Overweight
2019-07-22	Iniziato	SVB Leerink	Outperform

Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

05:19 AM

BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights

05:19 AM

05:12 AM

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat

05:12 AM

04:57 AM

Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech

04:57 AM

04:44 AM

BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks

04:44 AM

04:26 AM

Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business

04:26 AM

03:47 AM

BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news

03:47 AM

02:53 AM

BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com

02:53 AM

02:29 AM

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News

02:29 AM

02:25 AM

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighHere's What Happened - MarketBeat

02:25 AM

02:21 AM

BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com

02:21 AM

01:19 AM

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits

01:19 AM

12:52 PM

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - bitget.com

12:52 PM

12:44 PM

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga

12:44 PM

12:37 PM

BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus

12:37 PM

12:19 PM

BridgeBio gains on phase 3 dwarfism data - pharmaphorum

12:19 PM

11:51 AM

Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter

11:51 AM

11:33 AM

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive

11:33 AM

11:22 AM

BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz

11:22 AM

11:10 AM

BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada

11:10 AM

09:40 AM

BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com

09:40 AM

09:26 AM

BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat

09:26 AM

08:19 AM

BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha

08:19 AM

07:57 AM

BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada

07:57 AM

07:46 AM

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times

07:46 AM

07:45 AM

BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada

07:45 AM

07:43 AM

BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative

07:43 AM

07:40 AM

BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView

07:40 AM

07:31 AM

BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters

07:31 AM

04:33 AM

BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

04:33 AM

03:48 AM

Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily

03:48 AM

Feb 11, 2026

Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Feb 11, 2026

Feb 10, 2026

BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union

Feb 10, 2026

Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn

Feb 10, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 10, 2026

Feb 09, 2026

Buy the Dip on This Biotech Stock After Recent Fall - Finviz

Feb 09, 2026

BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance

Feb 09, 2026

BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection (NASDAQ:BBIO) - Seeking Alpha

Feb 09, 2026

Feb 08, 2026

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail

Feb 08, 2026

Feb 07, 2026

WCM Investment Management LLC Sells 14,253 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Feb 04, 2026